Author
K. Tzelepis
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2020-2023 · peak 2/yrCo-Author Collaboration Network
10 top collaborators · 14 mutual co-author links4 papers
Recent·Most cited
- Cell BiologybioRxivDOI 10.1016/j.cell.2025.01.040
- Cancer BiologybioRxiv
Mannose metabolism inhibition sensitizes acute myeloid leukemia cells to cytarabine and FLT3 inhibitor therapy by modulating fatty acid metabolism to drive ferroptotic cell death.
K. Woodley, L. S. Dillingh, G. Giotopoulos…·P. Gallipoli
This study shows that inhibiting mannose metabolism sensitizes AML cells to cytarabine and FLT3 inhibitors by promoting ferroptotic cell death through fatty acid metabolism changes.
DOI 10.1038/s41467-023-37652-0 - Pharmacology & ToxicologybioRxiv
Identification of SARS-CoV-2 induced pathways reveal drug repurposing strategies
N. Han, W. Hwang, K. Tzelepis…·T. Kouzarides
The paper identifies 200 approved drugs that target SARS-CoV-2-induced pathways, with 40 in clinical trials, and classifies them into viral replication and immune response mechanisms.
DOI 10.1126/sciadv.abh3032 - Cancer BiologybioRxivPreprint
KAT7 is a therapeutic vulnerability of MLL-rearranged acute myeloid leukemia
Y. Z. Au, M. Gu, E. De Braekeleer…·K. Yusa
This study identifies KAT7 as a critical therapeutic target in MLL-rearranged AML by showing its role in maintaining acetylation marks and supporting cell proliferation.